Biofrontera (BFRI) vs Sonoma Pharmaceuticals (SNOA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biofrontera is the larger company by market cap ($13.6 million vs $5.6 million), about 2.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BFRI | SNOA |
|---|---|---|
| Share price | $0.9188 | $1.16 |
| Market cap | $13.65M | $5.55M |
| 1-day change | -1.77% | -4.92% |
| YTD return | +61.19% | — |
| 1-year return | -9.03% | — |
| Forward P/E | 2.14 | — |
| EPS (TTM) | $-0.43 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.66 | $4.30 |
| 52-week low | $0.555 | $0.85 |
| Distance from 52-week high | -44.65% | -73.02% |
| Analyst consensus | none | — |
| Avg. price target upside | +553.03% | — |
| Average volume | 547.45K | 107.65K |
| Shares outstanding | 14.85M | 4.79M |
| Employees | 84 | 10 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Biofrontera is about 2.5 times larger than Sonoma Pharmaceuticals by market value ($13.65M vs $5.55M).
About Biofrontera
BFRI stock →Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Healthcare · Drug Manufacturers - Specialty & Generic · 84 employees
About Sonoma Pharmaceuticals
SNOA stock →Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally.
Healthcare · Drug Manufacturers - Specialty & Generic · 10 employees
BFRI vs SNOA FAQ
Which is bigger, Biofrontera or Sonoma Pharmaceuticals?
Biofrontera (BFRI) is larger, with a market capitalization of $13.65M compared with $5.55M for Sonoma Pharmaceuticals (SNOA).
Are Biofrontera and Sonoma Pharmaceuticals in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.